However, phase I clinical trials of Irosustat (STX64, 667Coumate), a potent STS inhibitor (307), in breast cancer patients demonstrated that blocking STS activity not only significantly reduced circulating E1S, but also lowered plasma DHEA and androstenedione concentrations, and if DHEA is indeed antiproliferative in breast cancer, this may have unwanted consequences for this treatment approach. The gene discussed is STS; the disease is breast carcinoma.